- Home
- VYNE vs CODX Comparison
VYNE vs CODX Comparison
Compare VYNE & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- CODX
- Stock Information
- Founded
- VYNE 2003
- CODX 2013
- Country
- VYNE United States
- CODX United States
- Employees
- VYNE N/A
- CODX N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- VYNE Health Care
- CODX Health Care
- Exchange
- VYNE Nasdaq
- CODX Nasdaq
- Market Cap
- VYNE 41.9M
- CODX 39.3M
- IPO Year
- VYNE 2018
- CODX 2017
- Fundamental
- Price
- VYNE $2.98
- CODX $1.05
- Analyst Decision
- VYNE Strong Buy
- CODX Hold
- Analyst Count
- VYNE 2
- CODX 1
- Target Price
- VYNE $6.88
- CODX $1.50
- AVG Volume (30 Days)
- VYNE 122.3K
- CODX 90.9K
- Earning Date
- VYNE 11-07-2024
- CODX 11-07-2024
- Dividend Yield
- VYNE N/A
- CODX N/A
- EPS Growth
- VYNE N/A
- CODX N/A
- EPS
- VYNE N/A
- CODX N/A
- Revenue
- VYNE $493,000.00
- CODX $7,321,012.00
- Revenue This Year
- VYNE $32.31
- CODX N/A
- Revenue Next Year
- VYNE N/A
- CODX N/A
- P/E Ratio
- VYNE N/A
- CODX N/A
- Revenue Growth
- VYNE 39.27
- CODX 57.16
- 52 Week Low
- VYNE $1.57
- CODX $1.00
- 52 Week High
- VYNE $4.09
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- VYNE 59.02
- CODX 34.55
- Support Level
- VYNE $2.65
- CODX $1.02
- Resistance Level
- VYNE $3.05
- CODX $1.08
- Average True Range (ATR)
- VYNE 0.23
- CODX 0.05
- MACD
- VYNE -0.05
- CODX -0.01
- Stochastic Oscillator
- VYNE 34.57
- CODX 21.74
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.